Immunotherapy is emerging in the clinical management of breast cancer, and PD-1 or PD-L1 antagonists are beginning to show early efficacy in several difficult-to-treat breast cancer subtypes, namely those that are triple negative, PD-L1 positive, or have higher levels of TILs [73]. This evidence concerns the gene CD274 and breast carcinoma.